Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Nestle, Stada prepare...

    Nestle, Stada prepare rival bids for Merck consumer health: sources

    Written by Ruby Khatun Khatun Published On 2017-12-06T09:00:52+05:30  |  Updated On 16 Aug 2021 5:43 PM IST

    LONDON/FRANKFURT: Swiss food giant Nestle and the private equity owners of German drug firm Stada are both preparing tentative bids for Merck KgaA's consumer health unit, several sources told Reuters.





    Merck's financial adviser JPMorgan has invited bids for the business, which is valued at about 4 billion euros ($4.8 billion), ahead of a Dec. 15 deadline, the sources said.

    Nestle is widely seen as a natural buyer for the maker of Seven Seas vitamins and Bion nutritional supplements after previous talks to set up a consumer joint venture with Merck fell through over the summer.



    Bain and Cinven, who earlier this year took control of Germany's Stada, are hoping to use the Merck unit as a buy-and-build platform for Stada, which makes generic drugs and consumer care products and had annual revenues of more than 2 billion euros in 2016, the sources said.

    The private equity firms are making an opportunistic move on Merck consumer health as they want to have options to build on the business they have with Stada, one of the sources said.



    Other buyout funds which do not have a presence in the consumer and healthcare industries and would not be able to use existing portfolio companies as an acquisition vehicle have been advised against entering the process, they said.

    Merck, which declined to comment, has seen enough interest from industry buyers, they said, pointing to takeover appetite from emerging markets.


    Nestle, Stada, Cinven, and Bain all declined to comment.


    Merck's vitamins and nutritional supplements would fit Nestle's ambition to expand in consumer healthcare, a fast-growing area CEO Mark Schneider has made a priority.


    Nestle has also been offered the $20 billion consumer health business that U.S. drug giant Pfizer is selling, the sources said.


    But Merck's portfolio is smaller and less diversified than Pfizer's and would keep Nestle closer to its core strength in packaged food, the sources said.


    Nestle, which wants to become a "nutrition, health and wellness company," promised shareholders in September that moving into consumer health would not be "a carte blanche for reckless diversification."


    Consumer health is a fragmented sector ranging from over-the-counter medicines and vitamins to sports nutrition products and condoms. It has proved fertile ground for deals in recent years, as aging populations and health-conscious consumers drive demand.


    Stada's owners are also mulling bids for the generic drug business being sold by Sanofi, the sources said and might favor this combination over Merck as generic drugs are typically valued at a cheaper multiple.


    Merck said in September that it would consider selling the $1 billion-a-year consumer health unit to help fund more research into prescription drugs.


    ($1 = 0.8401 euros)











    (Reporting by Pamela Barbaglia, Ludwig Burger, Patricia Weiss; Additional reporting by Arno Schuetze, Ben Hirschler, Dasha Afanasieva and Ben Martin; Writing by Martinne Geller; editing by Alexander Smith)









    AcquisitionBion nutritional supplementsconsumer healthgeneric drugsHealthcareJPMorganMark SchneiderMerckNestlenutritional supplementsPfizerrival bidsSeven Seas vitaminsStada
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok